Back to results
US 9,314,438 B2Granted
Elevation of the plasma HDL-cholesterol level
AssigneesAarhus Universitet, Region Midtjylland
InventorsKjeld Hermansen, Per Bendix Jeppesen
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneesAarhus Universitet, Region Midtjylland
InventorsKjeld Hermansen, Per Bendix Jeppesen
Estimating the term…
The present invention relates to the use of isosteviol, steviol, and related compounds for elevating the plasma HDL-cholesterol level. The invention furthermore relates to the use of these compounds for reducing the body weight of a subject and/or lowering the plasma triglyceride level of a subject, including a concomitant elevation of the plasma HDL-cholesterol level. Preferably the compounds used are isosteviol and/or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. The compounds may furthermore be administered in combination with one or more further active compounds, such as e.g. LDL-cholesterol lowering agents. The invention furthermore relates to a method for elevating the plasma HDL-cholesterol level in a subject by administering to a subject in need of such treatment a plasma HDL-cholesterol level elevating amount of the compounds, described herein.
A method for elevating the plasma HDL-cholesterol level in a human subject in need thereof, the method comprising administering to said human subject a daily dose of at least 100 mg of a plasma HDL-cholesterol level elevating amount of a compound selected from the group consisting of steviol and isosteviol, or a pharmaceutically acceptable salt or solvate thereof.
A method for elevating the plasma HDL-cholesterol level in a human subject by administering to a human subject in need of such treatment a daily dose of at least 100 mg of a plasma HDL-cholesterol level elevating amount of a compound selected from the group consisting of steviol and isosteviol, or a pharmaceutically acceptable salt or solvate thereof, and measuring the level of plasma HDL-cholesterol in the subject after administering the compound to detect elevated plasma HDL-cholesterol level in the subject.
Dependencies are inferred from the claim text.